Evidence map›Paper›PMID 21994772›Full record

ReviewViruses2011

The natural killer cell cytotoxic function is modulated by HIV-1 accessory proteins.

Bharatwaj Sowrirajan, Edward Barker

Abstract readReview
In one paragraph

Review in Viruses, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Virus-mediated inhibition of natural cytotoxicity receptor recognition.Cellular and molecular life sciences : CMLS · 2012
    Review
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Bharatwaj SowrirajanDepartment of Immunology and Microbiology, Rush University Medical Center, 1735 West Harrison St, Chicago, IL 60612, USA. bharatwaj_sowrirajan@rush.edu
Edward Barker

Funding

Vpu inhibits NK cell function through down regulation of NTB-AR01AI065361 · NIAID · UPSTATE MEDICAL UNIVERSITY · PI BARKER, EDWARD · 2006 to 2016
$2.9M
Modulation of surface markers by HIV-1 Vpu/Vpr and sensitivity to NK cell lysisR21AI081681 · NIAID · UNIVERSITY OF UTAH · PI BARKER, EDWARD, PLANELLES, VICENTE · 2009 to 2010
$423k
NIAID NIH HHS AI081681NIAID NIH HHS AI165361NIAID NIH HHS R01 AI065361NIAID NIH HHS R21 AI081681
6 · The paper itself

Abstract

Natural killer (NK) cells' major role in the control of viruses is to eliminate established infected cells. The capacity of NK cells to kill virus-infected cells is dependent on the interactions between ligands on the infected cell and receptors on the NK cell surface. Because of the importance of ligand-receptor interactions in modulating the NK cell cytotoxic response, HIV has developed strategies to regulate various NK cell ligands making the infected cell surprisingly refractory to NK cell lysis. This is perplexing because the HIV-1 accessory protein Vpr induces expression of ligands for the NK cell activating receptor, NKG2D. In addition, the accessory protein Nef removes the inhibitory ligands HLA-A and -B. The reason for the ineffective killing by NK cells despite the strong potential to eliminate infected cells is due to HIV-1 Vpu's ability to down modulate the co-activation ligand, NTB-A, from the cell surface. Down modulation of NTB-A prevents efficient NK cell degranulation. This review will focus on the mechanisms through which the HIV-1 accessory proteins modulate their respective ligands, and its implication for NK cell killing of HIV-infected cells.

Indexed as

HIV-1HIV InfectionsHumansKiller Cells, NaturalViral Regulatory and Accessory ProteinsViral Regulatory and Accessory ProteinsHIV-1NefNK cellsNKG2DNTB-APLC-γVprVpu

Identifiers

PMID21994772
PMCPMC3185792

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.